Laurus Labs Q2 Results: Net Profit Surges 126% to ₹441 Crore as Revenue Grows 33%

The Laurus Labs Q2 results show consolidated net profit of ₹441 crore for the quarter ended 30 September 2026, up 126% from ₹195 crore a year earlier, on revenue of ₹2,206 crore, up 33% from ₹1,653 crore. The Hyderabad-based drug maker said earnings before interest, tax, depreciation and amortisation (EBITDA) rose 78% to ₹762 crore at a margin of 34.5%. Growth was led by the contract development and manufacturing organisation (CDMO) business, which grew 75%. This explainer sets out the numbers, what drove them, what management said and what the company has not disclosed.

Laurus Labs Q2 results: key takeaways

• Revenue was ₹2,206 crore, up 33% from ₹1,653 crore a year earlier.
• Net profit was ₹441 crore, up 126% from ₹195 crore and about 20% higher than ₹368 crore in the previous quarter.
• EBITDA was ₹762 crore, up 78%, with a margin of 34.5%, about 850 basis points higher.
• CDMO revenue was ₹904 crore, up 75%; small-molecule CDMO was ₹875 crore, up 86%.
• Affordable Medicines, the generics business, earned ₹1,302 crore, up 15%.

Laurus Labs Q2 results by the numbers

Gross margin was 63%. For the first half of FY27, revenue was ₹4,233 crore, up 31%, EBITDA was ₹1,406 crore, up 72%, at a margin of 33.2%, and net profit was ₹809 crore against ₹358 crore a year earlier. By our own calculation, net profit grew 2.26 times year on year in the quarter, which is the 126% increase the company reports. The board declared an interim dividend of ₹1.00 per share. Shares closed 2.75% higher at ₹2,245 on the BSE, according to press reports. Company filings are available from BSE.

What drove the Laurus Labs Q2 results

The CDMO segment was the main engine. CDMO revenue of ₹904 crore was up 75%, and small-molecule CDMO of ₹875 crore was up 86%. For the half-year, CDMO revenue was ₹1,774 crore, up 71%. By our own calculation, CDMO contributed about 41% of the quarter’s revenue. The generics business, Affordable Medicines, grew more slowly, at 15% in the quarter to ₹1,302 crore and 13% in the half-year to ₹2,459 crore. The mix shift towards higher-margin contract work is consistent with the 850 basis point rise in EBITDA margin the company reports.

Why margins matter in the Laurus Labs Q2 results

Revenue grew 33% but EBITDA grew 78% and net profit 126%, so profit expanded much faster than sales. That pattern, known as operating leverage, appears when a larger share of revenue comes from higher-margin work and when fixed costs are spread over more output. The company reported a gross margin of 63% and an EBITDA margin of 34.5%. A margin of that size leaves room for a slowdown in growth without a collapse in profit, but it also raises the bar for future quarters, because investors will compare each result against this one. Whether the level is sustainable depends on contract mix, capacity use and input costs, none of which are detailed in the sources.

Sequential view of the Laurus Labs Q2 results

Compared with the previous quarter, profit rose about 20% from ₹368 crore to ₹441 crore. Year-on-year comparisons can flatter a result when the base was weak, and the base here, ₹195 crore, was low relative to the current quarter. The sequential figure is therefore a useful check: profit is still rising from a higher starting point, which suggests the improvement is not just a low-base effect. The sources do not provide a sequential revenue figure, so we have not calculated one.

Management commentary on the Laurus Labs Q2 results

Chief executive Dr Satyanarayana Chava described it as another record quarter. He said the company has commissioned its first commercial-scale peptide plant at Visakhapatnam, and that the proposed acquisition of Galenvs Sciences would add differentiated technology capabilities to its TIDES business, which covers peptides and oligonucleotides. More on the company is on its corporate website.

Research spending in the Laurus Labs Q2 results

Research and development spending including capital expenditure was ₹183 crore in the first half, or 4.3% of revenue, with ₹65 crore in the second quarter. Continued investment in development capability matters for a CDMO because customers choose partners on technical capability as well as price. The company did not break out in the figures we reviewed which projects the spending supports.

Market context from Acumen Research and Consulting

Acumen Research and Consulting’s HPAPI CDMO Market report values that market at USD 9.40 billion in 2025 and projects more than USD 27 billion by 2035, a CAGR of 11.1% for 2026 to 2035. It puts North America at about USD 3.57 billion, or 38%, with Asia Pacific growing faster at more than 12.4%. The report was updated in June 2026 and its FAQ value for 2026 does not fully reconcile with the stated CAGR, and it covers high-potency CDMO work rather than all of Laurus’s activities, so it is sector context only.

Timeline of the Laurus Labs Q2 results

• 30 September 2026: quarter ends.
• Late October 2026: Laurus reports Q2 FY27 results and declares an interim dividend.
• Same period: the company announces the proposed acquisition of 60% of Galenvs Sciences.

General background: why CDMO growth matters for Indian drug makers

Indian drug makers have traditionally earned most revenue from generics and active ingredients, where prices are competitive. CDMO work, in which a company develops and manufactures medicines for other firms, can offer longer contracts and higher margins. Customers are typically larger pharmaceutical and biotech firms that outsource development or manufacturing, and relationships can last for years. See more in our Pharmaceutical coverage.

Our analysis of the Laurus Labs Q2 results

In our assessment, the Laurus Labs Q2 results show a company whose profit growth is being driven by mix rather than by volume alone, with CDMO growth far exceeding generics growth. The sustainability of the margin depends on contract renewals and new capacity coming online.

What is not disclosed in the Laurus Labs Q2 results

• Customer names and contract values.
• Breakdown of CDMO growth by project.
• Guidance for the second half.

Risks and caveats

This article summarises the company’s reported results and press accounts. Quarterly results can include one-off items, and the sources do not detail any. It is news reporting and not investment advice.

What to watch next after the Laurus Labs Q2 results

• Ramp-up of the Visakhapatnam peptide plant.
• Completion of the Galenvs transaction.
• Third-quarter margins.

Questions readers ask about the Laurus Labs Q2 results

Is the profit rise from a one-off? The sources do not report one. Is generics growth slowing? It grew 15% in the quarter, slower than CDMO. Does the dividend change? An interim dividend of ₹1.00 per share was declared.

FAQ

How much profit did Laurus Labs make?

₹441 crore in the quarter, up 126%.

What was revenue?

₹2,206 crore, up 33%.

Which segment grew fastest?

Small-molecule CDMO, up 86%.

How we reported this: we relied on the company’s results announcement as reported, public company pages and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 30 October 2026. This is news reporting and not advice.